331 related articles for article (PubMed ID: 33000338)
1. Does androgen-deprivation therapy increase the risk of ischemic cardiovascular and cerebrovascular diseases in patients with prostate cancer? A nationwide population-based cohort study.
Kim DK; Lee HS; Park JY; Kim JW; Ha JS; Kim JH; Yang WJ; Cho KS
J Cancer Res Clin Oncol; 2021 Apr; 147(4):1217-1226. PubMed ID: 33000338
[TBL] [Abstract][Full Text] [Related]
2. Androgen-deprivation therapy and the risk of newly developed fractures in patients with prostate cancer: a nationwide cohort study in Korea.
Kim DK; Lee HS; Park JY; Kim JW; Ahn HK; Ha JS; Cho KS
Sci Rep; 2021 May; 11(1):10057. PubMed ID: 33980958
[TBL] [Abstract][Full Text] [Related]
3. Is androgen deprivation therapy associated with cerebral infarction in patients with prostate cancer? A Korean nationwide population-based propensity score matching study.
Tae BS; Jeon BJ; Choi H; Bae JH; Park JY
Cancer Med; 2019 Aug; 8(9):4475-4483. PubMed ID: 31183968
[TBL] [Abstract][Full Text] [Related]
4. Risk of cardiovascular intervention after androgen deprivation therapy in prostate cancer patients with a prior history of ischemic cardiovascular and cerebrovascular disease: A nationwide population-based cohort study.
Kim DK; Lee HS; Park JY; Kim JW; Hah YS; Ha JS; Kim JH; Cho KS
Urol Oncol; 2022 Jan; 40(1):6.e11-6.e19. PubMed ID: 34315660
[TBL] [Abstract][Full Text] [Related]
5. Risks of Major Long-Term Side Effects Associated with Androgen-Deprivation Therapy in Men with Prostate Cancer.
Nguyen C; Lairson DR; Swartz MD; Du XL
Pharmacotherapy; 2018 Oct; 38(10):999-1009. PubMed ID: 30080934
[TBL] [Abstract][Full Text] [Related]
6. Androgen deprivation therapy and cardiovascular risk: No meaningful difference between GnRH antagonist and agonists-a nationwide population-based cohort study based on 2010-2013 French Health Insurance data.
Scailteux LM; Vincendeau S; Balusson F; Leclercq C; Happe A; Le Nautout B; Polard E; Nowak E; Oger E
Eur J Cancer; 2017 May; 77():99-108. PubMed ID: 28390298
[TBL] [Abstract][Full Text] [Related]
7. Risk and timing of cardiovascular disease after androgen-deprivation therapy in men with prostate cancer.
O'Farrell S; Garmo H; Holmberg L; Adolfsson J; Stattin P; Van Hemelrijck M
J Clin Oncol; 2015 Apr; 33(11):1243-51. PubMed ID: 25732167
[TBL] [Abstract][Full Text] [Related]
8. Is androgen deprivation therapy for prostate cancer associated with cardiovascular disease? A meta-analysis and systematic review.
Liang Z; Zhu J; Chen L; Xu Y; Yang Y; Hu R; Zhang W; Song Y; Lu Y; Ou N; Liu X
Andrology; 2020 May; 8(3):559-574. PubMed ID: 31743594
[TBL] [Abstract][Full Text] [Related]
9. Correlation of Androgen Deprivation Therapy with Cognitive Dysfunction in Patients with Prostate Cancer: A Nationwide Population-Based Study Using the National Health Insurance Service Database.
Tae BS; Jeon BJ; Shin SH; Choi H; Bae JH; Park JY
Cancer Res Treat; 2019 Apr; 51(2):593-602. PubMed ID: 30025445
[TBL] [Abstract][Full Text] [Related]
10. Androgen deprivation therapy for prostate cancer and the risk of hematologic disorders.
Liu JM; Liu YP; Chuang HC; Wu CT; Su YL; Hsu RJ
PLoS One; 2020; 15(2):e0229263. PubMed ID: 32074125
[TBL] [Abstract][Full Text] [Related]
11. Cardiovascular disease risk and androgen deprivation therapy in patients with localised prostate cancer: a prospective cohort study.
Haque R; UlcickasYood M; Xu X; Cassidy-Bushrow AE; Tsai HT; Keating NL; Van Den Eeden SK; Potosky AL
Br J Cancer; 2017 Oct; 117(8):1233-1240. PubMed ID: 29017178
[TBL] [Abstract][Full Text] [Related]
12. Androgen-deprivation therapy and risk of death from cardio-vascular disease in prostate cancer patients: a nationwide lithuanian population-based cohort study.
Jonušas J; Drevinskaitė M; Patašius A; Kinčius M; Janulionis E; Smailytė G
Aging Male; 2022 Dec; 25(1):173-179. PubMed ID: 35882633
[No Abstract] [Full Text] [Related]
13. Relationship between Androgen Deprivation Therapy and Normal-Tension Glaucoma in Patients with Prostate Cancer: A Nationwide Cohort Study.
Ha JS; Lee HS; Park JY; Jeon J; Kim DK; Kim M; Hwang HS; Kim TH; Ahn HK; Cho KS
Yonsei Med J; 2022 Oct; 63(10):908-914. PubMed ID: 36168243
[TBL] [Abstract][Full Text] [Related]
14. Androgen deprivation therapy increases cardiovascular morbidity in men with prostate cancer.
Saigal CS; Gore JL; Krupski TL; Hanley J; Schonlau M; Litwin MS;
Cancer; 2007 Oct; 110(7):1493-500. PubMed ID: 17657815
[TBL] [Abstract][Full Text] [Related]
15. Androgen deprivation therapy for localized prostate cancer and the risk of cardiovascular mortality.
Tsai HK; D'Amico AV; Sadetsky N; Chen MH; Carroll PR
J Natl Cancer Inst; 2007 Oct; 99(20):1516-24. PubMed ID: 17925537
[TBL] [Abstract][Full Text] [Related]
16. The Risk of Cardiovascular Disease in Prostate Cancer Patients Receiving Androgen Deprivation Therapies.
Cardwell CR; O'Sullivan JM; Jain S; Harbinson MT; Cook MB; Hicks BM; McMenamin ÚC
Epidemiology; 2020 May; 31(3):432-440. PubMed ID: 31651660
[TBL] [Abstract][Full Text] [Related]
17. Androgen deprivation therapy for prostate cancer is associated with cardiovascular morbidity and mortality: a meta-analysis of population-based observational studies.
Zhao J; Zhu S; Sun L; Meng F; Zhao L; Zhao Y; Tian H; Li P; Niu Y
PLoS One; 2014; 9(9):e107516. PubMed ID: 25264674
[TBL] [Abstract][Full Text] [Related]
18. Quantifying observational evidence for risk of fatal and nonfatal cardiovascular disease following androgen deprivation therapy for prostate cancer: a meta-analysis.
Bosco C; Bosnyak Z; Malmberg A; Adolfsson J; Keating NL; Van Hemelrijck M
Eur Urol; 2015 Sep; 68(3):386-96. PubMed ID: 25484142
[TBL] [Abstract][Full Text] [Related]
19. Conventional androgen deprivation therapy is associated with an increased risk of cardiovascular disease in advanced prostate cancer, a nationwide population-based study.
Li JR; Wang SS; Chen CS; Cheng CL; Hung SC; Lin CH; Chiu KY
PLoS One; 2022; 17(6):e0270292. PubMed ID: 35763533
[TBL] [Abstract][Full Text] [Related]
20. Androgen Deprivation Therapy and Risk of Cardiovascular Disease in Patients With Prostate Cancer Based on Existence of Cardiovascular Risk.
Dragomir A; Touma N; Hu J; Perreault S; Aprikian AG
J Natl Compr Canc Netw; 2023 Feb; 21(2):163-171. PubMed ID: 36791755
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
